<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0709234153
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ROZLET 2.5 mg film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LETROZOLE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        165.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="EirGen Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            EirGen Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 488]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SPIMACO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SPIMACO ADDWAEIH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BG04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Rozlet tablets contain an active substance called letrozole. Letrozole belongs to a group of medicines called aromatase inhibitors. It is a hormonal (endocrine) breast cancer treatment.&nbsp;&nbsp;</p><p>Rozlet tablets are used to&nbsp;&nbsp;</p><p>- prevent breast cancer recurrences as first treatment after breast surgery or following five years of treatment with tamoxifen&nbsp;&nbsp;</p><p>- prevent breast tumours spreading to other parts of the body in patients in advanced stages of the disease&nbsp;&nbsp;</p><p><strong>Rozlet tablets should be used only for oestrogen receptor-positive breast cancer and only in women after menopause (when your periods have stopped completely).&nbsp;&nbsp;</strong></p><p>Growth of breast cancer is frequently stimulated by oestrogens, which are female sex hormones. Rozlet tablets reduce the amount of oestrogen by blocking an enzyme (aromatase) involved in the production of oestrogens. As a consequence tumour cells slow or stop growing and/or spreading to other parts of the body.&nbsp;&nbsp;</p><p>Rozlet tablets should only be taken under strict medical supervision. Your doctor will regularly monitor your condition to check if the treatment is having the desired effect. Rozlet tablets may cause thinning or wasting of your bones (osteoporosis) due to the reduction of oestrogens in your body (see Section 4 &ndash; Possible side effects). Your doctor may therefore decide to measure your bone density before, during and after treatment. If you have any questions about how Rozlet tablets work or why this medicine has been prescribed for you, ask your doctor.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Follow all the doctor&rsquo;s instructions carefully. They may differ from the general information in this leaﬂet.&nbsp;&nbsp;</strong></p><p><strong>Do not take Rozlet tablets if you&nbsp;&nbsp;</strong></p><p>- are allergic (hypersensitive) to letrozole or to any of the other ingredients of Rozlet tablets listed in section 6 of this leaflet&nbsp;&nbsp;</p><p>- still have periods (if you have not yet gone through menopause)&nbsp;&nbsp;</p><p>- are pregnant&nbsp;&nbsp;</p><p>- are breast-feeding&nbsp;</p><p>If any of the above conditions apply to you, tell your doctor before taking Rozlet tablets.&nbsp;&nbsp;</p><p><strong>Take special care with Rozlet tablets and talk to your doctor if you have&nbsp;&nbsp;</strong></p><p>- a severe kidney disease&nbsp;&nbsp;</p><p>- a severe liver disease&nbsp;&nbsp;</p><p>- a history of osteoporosis or bone fractures&nbsp;&nbsp;</p><p>If any of the above conditions apply to you, tell your doctor. Your doctor will take this into account during your treatment with Rozlet tablets.&nbsp;&nbsp;</p><p><strong>Taking other medicines</strong>:&nbsp;</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.&nbsp;&nbsp;</p><p><strong>Children and adolescents (below 18 years)</strong>&nbsp;</p><p>Rozlet tablets are not to be used in children or adolescents.&nbsp;&nbsp;</p><p><strong>Elderly (age 65 years and over)&nbsp;</strong></p><p>Rozlet tablets can be used by people aged 65 years and over. The dose is the same for older people as it is for other adults.&nbsp;&nbsp;</p><p><strong>Taking Rozlet tablets with food and drink&nbsp;</strong></p><p>Rozlet tablets can be taken with or without food or a drink.&nbsp;&nbsp;</p><p><strong>Pregnancy and breast-feeding&nbsp;</strong></p><p>You must not take Rozlet tablets if you are pregnant or breast feeding as it may harm your baby. If you are pregnant or are currently breast-feeding, tell your doctor before taking Rozlet tablets. However, since Rozlet tablets are only recommended for postmenopausal women, pregnancy and breast-feeding restrictions most likely will not apply to you. However, if you recently became postmenopausal or if you are perimenopausal, your doctor should discuss with you about the necessity of a pregnancy test before taking letrozole and of a contraception as you might have the potential to become pregnant.&nbsp;&nbsp;</p><p><strong>Driving and using machines:&nbsp;</strong></p><p>If you feel dizzy, tired, drowsy or generally unwell, do not drive or operate any tools or machines until you feel normal again.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Rozlet tablets exactly as your doctor has told you. You should check with your doctor or your pharmacist if you are not sure.&nbsp;&nbsp;</p><p><strong>Dosage&nbsp;</strong></p><p>The usual dose is one tablet taken once a day. Taking Rozlet tablets at the same time each day will help you remember when to take your tablet.&nbsp;&nbsp;</p><p><strong>Method of administration&nbsp;&nbsp;</strong></p><p>The tablet should be swallowed whole with a glass of water or another liquid.&nbsp;&nbsp;</p><p><strong>Duration of treatment&nbsp;&nbsp;</strong></p><p>Continue taking Rozlet tablets every day for as long as your doctor tells you. You may need to take them for months or even years. If you have any questions about how long to keep taking Rozlet tablets, talk to your doctor.&nbsp;&nbsp;</p><p><strong>If you take more Rozlet tablets than you should&nbsp;</strong></p><p>If you have taken too much Rozlet tablets, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice immediately. Show them the pack of tablets. Medical treatment may be necessary.&nbsp;&nbsp;</p><p><strong>If you forget to take Rozlet tablets&nbsp;&nbsp;</strong></p><p>- If it is almost time for your next dose (e.g. within 2 or 3 hours), skip the dose you missed and take your next dose when you are meant to.&nbsp;&nbsp;</p><p>- Otherwise, take the dose as soon as your remember, and then take the next tablet as you would normally.&nbsp;&nbsp;</p><p>- Do not take a double dose to make up for the one that you missed.&nbsp;&nbsp;</p><p><strong>If you stop taking Rozlet tablets&nbsp;</strong></p><p>Do not stop taking Rozlet tablets unless your doctor tells you. See also the section above &ldquo;Duration of treatment&rdquo;.&nbsp;&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Rozlet tablets can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment. Some of them, such as hot flushes, hair loss or vaginal bleeding, may be due to the lack of oestrogens in your body. Do not be alarmed by this list of possible side effects. You may not experience any of them.&nbsp;&nbsp;</p><p><strong>Serious side effects&nbsp;</strong>&nbsp;</p><p>These side effects are rare or uncommon (affect less than 1 in every 100 patients), but do require <strong>immediate medical attention.&nbsp;&nbsp;</strong></p><p>- Some patients experienced swelling mainly of the face and throat (signs of allergic reaction) during treatment with Rozlet tablets&nbsp;&nbsp;</p><p>- weakness, paralysis, loss of feeling in an arm or leg or any other part of the body, loss of coordination, nausea, difficulty in speaking or breathing (sign of a brain disorder, such as a stroke)&nbsp;&nbsp;</p><p>- Sudden oppressive chest pain (sign of a heart disorder)&nbsp;&nbsp;</p><p>- difficulty in breathing, chest pain, fainting, rapid heart rate, bluish skin discoloration, sudden arm or leg (foot) pain (signs that a blood clot may have formed)&nbsp;&nbsp;</p><p>- Swelling and redness along a vein which is extremely tender and possibly painful when touched&nbsp;&nbsp;</p><p>- Severe fever, chills or mouth ulcers due to infections (lack of white blood cells)&nbsp;&nbsp;</p><p>- Severe persistent blurred vision&nbsp;&nbsp;</p><p><strong>If you are having any of the above, tell your doctor straight away.&nbsp;&nbsp;</strong></p><p><u>Other reported side effects&nbsp;&nbsp;</u></p><p><strong>Very common side effects (affect more than 10 in every 100 patients)&nbsp;&nbsp;</strong></p><p>- Hot flushes&nbsp;&nbsp;</p><p>- Increased level of cholesterol (hypercholesterolaemia).&nbsp;</p><p>- Fatigue&nbsp;&nbsp;</p><p>- Increased sweating&nbsp;&nbsp;</p><p>- Pain in bones and joints (arthralgia)&nbsp;&nbsp;</p><p>If any of these affects you severely, tell your doctor.&nbsp;&nbsp;</p><p><strong>Common side effects (may affect between 1 and 10 in every 100 patients)&nbsp;&nbsp;</strong></p><p>- Skin rash&nbsp;&nbsp;</p><p>- Headache&nbsp;&nbsp;</p><p>- Dizziness&nbsp;&nbsp;</p><p>- Malaise (generally feeling unwell)&nbsp;&nbsp;</p><p>- Gastrointestinal disorders such as nausea, vomiting, indigestion, constipation, diarrhoea&nbsp;&nbsp;</p><p>- Increase in or loss of appetite&nbsp;&nbsp;</p><p>- Pain in muscles&nbsp;&nbsp;</p><p>- thinning or wasting of your bones (osteoporosis), leading to bone fractures in some cases&nbsp;&nbsp;</p><p>- swelling of arms, hands, feet, ankles (oedema)&nbsp;</p><p>- Depression&nbsp;&nbsp;</p><p>- Weight increase&nbsp;&nbsp;</p><p>- Hair loss&nbsp;</p><p>- Raised blood pressure (hypertension)&nbsp;</p><p>- Abdominal pain&nbsp;</p><p>- Dry skin&nbsp;</p><p>- Vaginal bleeding&nbsp;</p><p>- Palpitations, rapid heart rate&nbsp;</p><p>- Joint stiffness (arthritis)&nbsp;</p><p>- Chest pain&nbsp;&nbsp;</p><p>If any of these affects you severely, tell your doctor.&nbsp;&nbsp;</p><p><strong>Uncommon side effects (may affect between 1 and 10 in every 1,000 patients)&nbsp;&nbsp;</strong></p><p>- Nervous disorders such as anxiety, nervousness, irritability, drowsiness, memory problems, somnolence, insomnia&nbsp;&nbsp;</p><p>- Pain or burning sensation in the hands or wrist (carpal tunnel syndrome)&nbsp;</p><p>- Impairment of sensation, especially that of touch&nbsp;&nbsp;</p><p>- Eye disorders such as blurred vision or eye irritation&nbsp;&nbsp;</p><p>- Skin disorders such as itching (urticaria).&nbsp;</p><p>- Vaginal discharge or dryness&nbsp;&nbsp;</p><p>- Breast pain&nbsp;&nbsp;</p><p>- Fever&nbsp;&nbsp;</p><p>- Thirst, taste disorder, dry mouth&nbsp;&nbsp;</p><p>- Dryness of mucous membranes&nbsp;&nbsp;</p><p>- Weight decrease&nbsp;&nbsp;</p><p>- Urinary tract infection, increased frequency of urination&nbsp;&nbsp;</p><p>- cough&nbsp;&nbsp;</p><p>- Increased level of enzymes&nbsp;</p><p>- Yellowing of the skin and eyes&nbsp;</p><p>- High blood levels of bilirubin (a breakdown product of red blood cells)&nbsp;</p><p>If any of these affects you severely, tell your doctor.&nbsp;&nbsp;</p><p>&nbsp;</p><p><strong>Side effects with frequency not known </strong>(frequency cannot be estimated from the available data)&nbsp;</p><p>Trigger finger, a condition in which your finger or thumb catches in bent position.&nbsp;</p><p>If any of these affects you severely, tell your doctor.&nbsp;&nbsp;</p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaﬂet, please tell your doctor or pharmacist.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.&nbsp;</p><p>Do not store above 30&deg;C.&nbsp;</p><p>Do not use Rozlet tablets after the expiry date which is stated on the carton and the blister after EXP. The expiry date refers to the last day of that month.&nbsp;</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is letrozole. Each film-coated tablet contains 2.5 mg letrozole. The other ingredients are cellulose microcrystalline, silica colloidal anhydrous, sodium starch glycolate, and magnesium stearate. The coating is composed of polyvinyl alcohol, polyethylene glycol, titanium dioxide (E171), talc, yellow iron oxide (E172), Sunset Yellow FCF (E110).&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Rozlet tablets are supplied as film-coated tablets. The film-coated tablets are yellow and round, biconvex in shape, with “2.5” imprinted on one side of the tablet and plain on the reverse. Each blister pack contains 10, 14, 28, 30, or 100 film-coated tablets. 
Not all pack sizes may be marketed 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufactured by:&nbsp;</p><p>EirGen Pharma Ltd.&nbsp;</p><p>Westside Business Park,&nbsp;</p><p>Old Kilmeaden Road, Waterford,&nbsp;</p><p>Ireland.&nbsp;</p><p>For&nbsp;&nbsp;</p><p>SPIMACO&nbsp;</p><p>AlQassim pharmaceutical plant&nbsp;</p><p>Saudi Arabia&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                December 2018.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي أقراص روزليت على مادة فعالة تدعي ليتروزول. ينتمي ليتروزول إلى مجموعة من الأدوية تسمى مثبطات الهرمونات. وهو علاج هرموني (الغدد الصماء) لسرطان الثدي.</p><p>وتستخدم أقراص روزليت في:</p><p>- منع تكرار الإصابة بسرطان الثدي والعلاج الأولى بعد جراحة الثدي أو بعد خمس سنوات من العلاج بعقار تاموكسيفين.</p><p>- منع انتشار أورام الثدي إلى أجزاء أخرى من الجسم لدى المرضى في المراحل المتقدمة من المرض.</p><p>&nbsp;</p><p><strong>ينبغي أن تستخدم أقراص روزليت فقط في حالة سرطان الثدي المميز بمستقبلات هرمون الاستروجين الإيجابية و فقط في النساء بعد انقطاع الطمث (عند انقطاع الدورة تماما).</strong></p><p>كثيرا ما يتم تحفيز نمو سرطان الثدي بنسبة الاستروجين، والتي هي الهرمونات الجنسية الأنثوية. روزليت أقراص تقلل من كمية هرمون الاستروجين عن طريق منع الإنزيم (الأروماتيز) المشارك في إنتاج الاستروجين. ونتيجة لهذا سوف تبطئ الخلايا السرطانية أو تتوقف عن النمو و / أو تتوقف عن الإنتشار إلى أجزاء أخرى من الجسم.</p><p>يجب فقط أن تؤخذ أقراص روزليت تحت إشراف طبي صارم. طبيبك سوف يراقب بانتظام الحالة لمعرفة ما إذا كان العلاج قد أحدث التأثير المطلوب. قد تتسبب أقراص روزليت في الترقق أو الهزال في عظامك (هشاشة العظام) نظرا لانخفاض الاستروجين في جسمك (انظر الفقرة 4 - الآثار الجانبية المحتملة). ولذلك قد يقرر طبيبك قياس كثافة العظام قبل وأثناء وبعد العلاج. إذا كانت لديك أي أسئلة حول كيفية عمل أقراص روزليت أو لماذا تم وصف هذا الدواء لك، قم باستشارة طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>اتبع جميع تعليمات الطبيب بدقة. وقد تختلف عن المعلومات العامة في هذه النشرة.</p><p><strong>لا تتناول أقراص روزليت إذا كنت</strong></p><p>- لديك حساسية (حساسية مفرطة) ل ليتروزول أو إلى أي من المكونات الأخرى لأقراص روزليت المذكورة في الفقرة 6 من هذه النشرة.</p><p>- لا تزال الدورة منتظمة (إذا لم تصل حتى الآن إلى مرحلة انقطاع الطمث).</p><p>- حاملا.</p><p>- تقومين بالرضاعة الطبيعية.</p><p>إذا كانت أي من الشروط المذكورة أعلاه تنطبق عليك، أخبري طبيبك قبل تناول أقراص روزليت.</p><p>&nbsp;</p><p><strong>تحتاج عناية خاصة أثناء تناول أقراص روزليت واستشارة طبيبك إذا كان لديك</strong></p><p>- مرض الكلى الحاد.</p><p>- مرض الكبد الحاد.</p><p>- تاريخ من مرض هشاشة العظام أو الكسور العظمية.</p><p>إذا كانت أي من الشروط المذكورة أعلاه تنطبق عليك، أخبر طبيبك. سوف يضع طبيبك كل هذا في الاعتبار أثناء علاجك باستخدام أقراص روزليت.</p><p>تناول أدوية أخرى:</p><p>يرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها دون وصفة طبية.</p><p><strong>الأطفال والمراهقين (أقل من 18 سنة)</strong></p><p>لا تستخدم أقراص روزليت في الأطفال أو المراهقين.</p><p><strong>كبار السن (العمر 65 سنة وما فوق)</strong></p><p>أقراص روزليت يمكن استخدامها من قبل المرضي الذين تتراوح أعمارهم بين 65 سنة وما فوق. الجرعة بالنسبة لكبار السن هي نقس الجرعة التي يتناولها غيرهم من البالغين.</p><p><strong>تناول أقراص روزليت مع الطعام والشراب</strong></p><p>يمكن تناول أقراص روزليت مع أو بدون الطعام أو الشراب.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>لا يجب أن تتناولي أقراص روزليت إذا كنت حاملا أو تقومين بالرضاعة الطبيعية لأن هذا قد يضر طفلك. إذا كنت حاملا أو تقومين حاليا بالرضاعة الطبيعية، عليك إخبار طبيبك قبل تناول أقراص روزليت. على الرغم من أنه لا ينصح بتناول أقراص روزليت إلا للنساء فيما بعد انقطاع الطمث، وبذلك لن تنطبق عليك قيود عدم تناول الدواء في الحمل والرضاعة.</p><p>ومع ذلك، إذا كنت حديثة العهد بسن اليأس أو في فترة ما قبل سن اليأس، يجب مناقشة الطبيب معك حول ضرورة وجود اختبار الحمل ووسائل منع الحمل قبل تناول ليتروزول لأن لديك الفرصة أن تكوني حاملا.</p><p><strong>القيادة واستخدام الآلات:</strong></p><p>إذا كنت تشعر بالدوار، أوالتعب، أو النعاس أو عموما أنك لست علي ما يرام، لا تقم بالقيادة أو تشغيل أي أدوات أو آلات حتى تشعر بأنك عدت لحالتك الطبيعية مرة أخرى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>دائما تناول أقراص روزليت كما أخبرك طبيبك تماما. يجب أن تستشير طبيبك أو الصيدلي إذا كنت غير متأكد.</p><p><strong>الجرعة</strong></p><p>الجرعة المعتادة هي حبة واحدة يتم تناولها مرة واحدة في اليوم. تناول أقراص روزليت في نفس الوقت كل يوم سوف يساعدك على تذكر متي يجب عليك تناول القرص.</p><p><strong>طريقة الاستعمال</strong></p><p>يجب ابتلاع القرص كاملا مع كوب من الماء أو أي سائل أخر.</p><p><strong>فترة العلاج</strong></p><p>استمر في تناول أقراص روزليت يوميا طوال الفترة التي أخبرك بها طبيبك. قد تحتاج إلى تناولها لعدة أشهر أو حتى سنوات. إذا كانت لديك أي أسئلة حول مدة الفترة التي يتوجب عليك فيها تناول أقراص روزليت، قم بالتحدث مع طبيبك.</p><p><strong>إذا تناولت أقراص روزليت أكثر مما يجب</strong></p><p>إذا تناولت الكثير من أقراص روزليت، أو إذا تناول شخص آخر بطريق الخطأ الأقراص الخاصة بك، اتصل بطبيبك أو المستشفى على الفور للحصول على المشورة. قم بإظهار علبة الأقراص. قد يكون العلاج الطبي ضروريا في هذه الحالة.</p><p>&nbsp;</p><p><strong>إذا نسيت أن تتناول أقراص روزليت</strong></p><p>- إذا كان الوقت تقريبا هو نفس ميعاد الجرعة التالية الخاصة بك (على سبيل المثال في حدود 2 أو 3 ساعات)، قم بتخطي الجرعة التي نسيتها وقم بتناول الجرعة التالية فى وقتها.</p><p>- خلاف ذلك، تناول الجرعة عندما تتذكر، وبعد ذلك قم بتناول دوائك كالمعتاد.</p><p>- لا تقم بتناول جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>&nbsp;</p><p><strong>إذا توقفت عن تناول أقراص روزليت</strong></p><p>لا تتوقف عن تناول أقراص روزليت إذا لم يخبرك طبيبك بهذا. انظر أيضا الفقرة أعلاه &quot; فترة العلاج &ldquo;.</p><p>إذا كانت لديك أي أسئلة أخرى حول استخدام هذا الدواء، قم باستشارة طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن تتسبب أقراص روزليت في آثار جانبية، على الرغم من أنه ليس من الضروري أن تحدث لجميع من يتناولون الدواء. معظم الآثار الجانبية خفيفة الى متوسطة، وسوف تختفي عادة بعد بضعة أيام إلى بضعة أسابيع من العلاج. البعض منهم، مثل الهبات الساخنة، وسقوط الشعر أو النزيف المهبلي، قد يرجع إلى عدم وجود الاستروجين في الجسم. لا تنزعج من هذه القائمة من الآثار الجانبية المحتملة الحدوث فقد لا يحدث لك أي منها.</p><p>&nbsp;</p><p><strong>آثار جانبية خطيرة</strong></p><p>هذه الآثار الجانبية نادرة أو غير شائعة (تؤثر على أقل من 1 في كل 100 مريض)، ولكن لا تتطلب عناية طبية فورية.</p><p>- ظهر في بعض المرضى تورم في الوجه والحلق بشكل محدد (علامات الحساسية) خلال فترة العلاج مع أقراص روزليت.</p><p>- الضعف، والشلل، وفقدان الإحساس في الذراع أو الساق أو أي جزء آخر من الجسم، وفقدان تناسق الحركة، والغثيان، والصعوبة في الكلام أو التنفس (علامة على وجود اضطراب في الدماغ، مثل السكتة الدماغية).</p><p>- ألم في الصدر القمعي المفاجئ (علامة على وجود اضطرابات في القلب).</p><p>- صعوبة في التنفس، ألم في الصدر، إغماء، سرعة في معدل دقات القلب، تلون الجلد المزرق، ألم مفاجئ في الذراع أو الساق (القدم) (دلائل على تكون جلطة دموية).</p><p>- تورم واحمرار على طول الوريد الذي هو غاية في الرقة ومن الممكن أن يكون مؤلما عند لمسه.</p><p>- الحمى الشديدة والرعشة أو القرحة بسبب التهابات الفم (نقص خلايا الدم البيضاء).</p><p>- عدم وضوح الرؤية بشكل حاد ومستمر.</p><p>إذا كنت تواجه أي من الآثار الموجودة أعلاه، أخبر طبيبك فورا.</p><p><u>الآثار الجانبية الأخرى المبلغ عنها</u></p><p><strong>الآثار الجانبية الشائعة جدا </strong>(يؤثر في أكثر من 10 في كل 100 مريض )</p><p>- الهبات الساخنة.</p><p>- ارتفاع مستوى الكوليستيرول في الدم.</p><p>- التعب.</p><p>- زيادة التعرق.</p><p>- ألم في العظام والمفاصل (ألم مفصلي).</p><p>إذا كانت أي من هذه الآثار تؤثر عليك بشدة، أخبر طبيبك.</p><p><strong>الآثار الجانبية الشائعة (قد تؤثر فيما بين 1 و10 في كل 100 مريض)</strong></p><p>- طفح جلدي.</p><p>- صداع.</p><p>- دوخة.</p><p>- الشعور بالضيق (الشعور العام بأنك لست على ما يرام).</p><p>- اضطرابات الجهاز الهضمي مثل الغثيان، والتقيؤ، عسر الهضم، والإمساك، والإسهال.</p><p>- زيادة أو فقدان الشهية.</p><p>- ألم في العضلات.</p><p>- ترقق أو هزال في عظامك (هشاشة العظام)، مما يؤدي لكسور العظام في بعض الحالات.</p><p>- تورم في الذراعين واليدين والقدمين والكاحلين (وذمة)</p><p>- الاكتئاب.</p><p>- زيادة الوزن.</p><p>- سقوط الشعر.</p><p>- ارتفاع ضغط الدم.</p><p>- آلام في البطن.</p><p>- جفاف الجلد.</p><p>- النزيف المهبلي.</p><p>- خفقان القلب، سرعة معدل ضربات القلب.</p><p>- تصلب المفاصل (التهاب المفاصل).</p><p>- ألم في الصدر.</p><p>إذا كانت أي من هذه الآثار تؤثر عليك بشدة، أخبر طبيبك.</p><p><strong>الآثار الجانبية غير الشائعة (قد تؤثر فيما بين 1 و10 في كل من 1000 مريض)</strong></p><p>- اضطرابات عصبية مثل القلق، والعصبية، والتهيج، والنعاس، مشاكل في الذاكرة، نعاس، أرق.</p><p>- الاحساس بالألم أو الحرقان في الأيدي أو في المعصم (متلازمة النفق الرسغي).</p><p>- ضعف الإحساس، وخصوصا المتعلق باللمس.</p><p>- اضطرابات العين مثل عدم وضوح الرؤية أو حساسية العين.</p><p>- اضطرابات الجلد مثل الحكة (الشرى).</p><p>- الإفرازات المهبلية أو الجفاف.</p><p>- ألم الثدي.</p><p>- حمى.</p><p>- العطش، واضطراب التذوق، وجفاف الفم.</p><p>- جفاف الأغشية المخاطية.</p><p>- نقص الوزن.</p><p>- التهاب المسالك البولية، وزيادة تواتر التبول.</p><p>- السعال.</p><p>- ارتفاع مستوى الإنزيمات.</p><p>- اصفرار في الجلد والعينين.</p><p>- ارتفاع مستويات البيليروبين في الدم (ينتج عن تكسير خلايا الدم الحمراء).</p><p>&nbsp;</p><p>إذا كانت أي من هذه الآثار تؤثر عليك بشدة، أخبر طبيبك.</p><p>&nbsp;</p><p><strong>الآثار الجانبية غير معروف معدل تكرارها </strong>(لا يمكن تقدير معدل تكرارها من البيانات المتاحة)</p><p>إصبع الزناد ، وهي حالة يأخذ فيها إصبعك أو إبهامك وضع التقوس.</p><p>&nbsp;</p><p>إذا كانت أي من هذه الآثار تؤثر عليك بشدة، أخبر طبيبك.</p><p>&nbsp;</p><p>إذا أصبحت أي من الأثار الجانبية أكثر سوءا، أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدا عن متناول وبصر الأطفال.</p><p>- لا يحفظ في درجة حرارة أعلي من 30 درجة مئوية.</p><p>- لا تستعمل أقراص روزليت بعد انتهاء تاريخ الصلاحية المدون على العبوة والشريط بعد كلمة Exp. وتاريخ الإنتهاء يشير إلى أخر يوم فى الشهر المذكور.</p><p>- لا ينبغي التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير علي حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي ليتروزول. كل قرص مغلف بطبقة رقيقة يحتوي على 2.5 ملجم ليتروزول.</p><p>المكونات الأخرى:</p><p>الكريستالات المصغرة من السيليولوز، السيليكا الغروية اللامائية، جلايكولات نشا الصوديوم، وستيارات الماغنسيوم. ويتكون الطلاء من بولي فينيل الكحول، بولي ايثيلين جلايكول، وأكسيد الحديد الأصفر، وثاني أكسيد التيتانيوم (E171)، التلك، أكسيد الحديد الأصفر (E172)، السنسيت الأصفر FCF (E110)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>يتم توفير أقراص روزليت على شكل أقراص مغلفة بطبقة رقيقة. الأقراص المغلفة الرقيقة تكون باللون الأصفر وتكون دائرية، ثنائية التحدب في الشكل، مع &quot; 2.5 &quot; مطبوع على جانب واحد من القرص ومنبسط بشكل عادي على الجانب الأخر. كل عبوة تحتوي على 10، 14، 28، 30، أو 100 قرص مغلف بطبقة رقيقة. ليست كل العبوات متاحة للتسويق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>المصنع:</p><p>إيرجين فارما المحدودة.</p><p>الجانب الغربى من مدينة بزنس بارك،</p><p>طريق كيلميدين القديم. وترفورد،</p><p>أيرلندا.</p><p>&nbsp;</p><p>لصالح:</p><p>الدوائية</p><p>مصنع الأدوية بالقصيم</p><p>المملكة العربية السعودية</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ديسمبر 2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rozlet® 2.5 mg Film coated tablets. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Active substance: letrozole. 
Each film-coated tablet contains 2.5 mg letrozole. 
For the full list of excipients, see section 6.1. 

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet
Yellow, round, biconvex, film-coated, tablets. Debossed "2.5" on one side, plain on reverse.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><ul><li><p>Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer.&nbsp;</p></li><li><p>Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.&nbsp;</p></li><li><p>First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer.&nbsp;</p></li><li><p>Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal endocrine status, who have previously been treated with anti-oestrogens.&nbsp;</p></li><li><p>Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.&nbsp;</p></li></ul><p>Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology&nbsp;</u></p><p><em>Adult and elderly patients&nbsp;</em></p><p>The recommended dose of Rozlet is 2.5 mg once daily. No dose adjustment is required for elderly patients.&nbsp;</p><p>In patients with advanced or metastatic breast cancer, treatment with Rozlet should continue until tumour progression is evident.&nbsp;</p><p>In the adjuvant and extended adjuvant setting, treatment with Rozlet should continue for 5 years or until tumour relapse occurs, whichever is first.&nbsp;</p><p>In the adjuvant setting a sequential treatment schedule (letrozole 2 years followed by tamoxifen 3 years) could also be considered (see sections 4.4 and 5.1).&nbsp;</p><p>In the neoadjuvant setting, treatment with Rozlet could be continued for 4 to 8 months in order to establish optimal tumour reduction. If the response is not adequate, treatment with Rozlet should be discontinued and surgery scheduled and/or further treatment options discussed with the patient.&nbsp;</p><p><em>Paediatric population&nbsp;</em></p><p>Rozlet is not recommended for use in children and adolescents. The safety and efficacy of Rozlet in children and adolescents aged up to 17 years have not been established. Limited data are available and no recommendation on a posology can be made.&nbsp;</p><p><em>Renal impairment&nbsp;</em></p><p>No dosage adjustment of Rozlet is required for patients with renal insufficiency with creatinine clearance &ge;10 ml/min. Insufficient data are available in cases of renal insufficiency with creatinine clearance lower than 10 ml/min (see sections 4.4 and 5.2).&nbsp;</p><p><em>Hepatic impairment&nbsp;</em></p><p>No dose adjustment of Rozlet is required for patients with mild to moderate hepatic insufficiency (Child-Pugh A or B). Insufficient data are available for patients with severe hepatic impairment. Patients with severe hepatic impairment (Child-Pugh C) require close supervision (see sections 4.4 and 5.2).&nbsp;</p><p><u>Method of administration&nbsp;</u></p><p>Rozlet should be taken orally and can be taken with or without food.&nbsp;</p><p>A missed dose should be taken as soon as the patient remembers. However, if it is almost time for the next dose (within 2 or 3 hours), the missed dose should be skipped, and the patient should go back to her regular dosage schedule. Doses should not be doubled because with daily doses over the 2.5 mg recommended dose, over-proportionality in systemic exposure was observed (see section 5.2).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                ••Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 
• Premenopausal endocrine status 
• Pregnancy (see section 4.6) 
•  Breast-feeding (see section 4.6) 

 
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Menopausal status&nbsp;</u></p><p>In patients whose menopausal status is unclear, luteinising hormone (LH), follicle-stimulating hormone (FSH) and/or oestradiol levels should be measured before initiating treatment with Rozlet. Only women of postmenopausal endocrine status should receive Rozlet.&nbsp;</p><p><u>Renal impairment&nbsp;</u></p><p>Rozlet has not been investigated in a sufficient number of patients with a creatinine clearance lower than 10 ml/min. The potential risk/benefit to such patients should be carefully considered before administration of Rozlet.&nbsp;</p><p><u>Hepatic impairment&nbsp;</u></p><p>In patients with severe hepatic impairment (Child-Pugh C), systemic exposure and terminal half-life were approximately doubled compared to healthy volunteers. Such patients should therefore be kept under close supervision (see section 5.2).&nbsp;</p><p><u>Bone effects&nbsp;</u></p><p>Rozlet is a potent oestrogen-lowering agent. Women with a history of osteoporosis and/or fractures, or who are at increased risk of osteoporosis, should have their bone mineral density formally assessed prior to the commencement of adjuvant and extended adjuvant treatment and monitored during and following treatment with letrozole. Treatment or prophylaxis for osteoporosis should be initiated as appropriate and carefully monitored. In the adjuvant setting a sequential treatment schedule (letrozole 2 years followed by tamoxifen 3 years) could also be considered depending on the patient&#39;s safety profile (see sections 4.2, 4.8 and 5.1).&nbsp;</p><p><u>Other warnings&nbsp;</u></p><p>Co-administration of Rozlet with tamoxifen, other anti-oestrogens or oestrogen-containing therapies should be avoided as these substances may diminish the pharmacological action of letrozole (see section 4.5).&nbsp;</p><p>As the film coated tablets contain lactose, Rozlet is not recommended for patients with rare hereditary problems of galactose intolerance, of severe lactase deficiency or of glucose-galactose malabsorption.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Metabolism of letrozole is partly mediated via CYP2A6 and CYP3A4. Cimetidine, a weak, unspecific inhibitor of CYP450 enzymes, did not affect the plasma concentrations of letrozole. The effect of potent CYP450 inhibitors is unknown.&nbsp;</p><p>There is no clinical experience to date on the use of Rozlet in combination with oestrogens or other anticancer agents, other than tamoxifen. Tamoxifen, other anti-oestrogens or oestrogen-containing therapies may diminish the pharmacological action of letrozole. In addition, co-administration of tamoxifen with letrozole has been shown to substantially decrease plasma concentrations of letrozole. Co-administration of letrozole with tamoxifen, other anti-oestrogens or oestrogens should be avoided.&nbsp;</p><p><em>In vitro</em>, letrozole inhibits the cytochrome P450 isoenzymes 2A6 and, moderately, 2C19, but the clinical relevance is unknown. Caution is therefore indicated when giving letrozole concomitantly with medicinal products whose elimination is mainly dependent on these isoenzymes and whose therapeutic index is narrow (e.g. phenytoin, clopidrogel).&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of perimenopausal status or child-bearing potential&nbsp;</u></p><p>Rozlet should only be used in women with a clearly established postmenopausal status (see section 4.4). As there are reports of women regaining ovarian function during treatment with Rozlet despite a clear postmenopausal status at start of therapy, the physician needs to discuss adequate contraception when necessary.&nbsp;</p><p><u>Pregnancy&nbsp;</u></p><p>Based on human experience in which there have been isolated cases of birth defects (labial fusion, ambiguous genitalia), Rozlet may cause congenital malformations when administered during pregnancy. Studies in animals have shown reproductive toxicity (see section 5.3).&nbsp;</p><p>Rozlet is contraindicated during pregnancy (see sections 4.3 and 5.3).&nbsp;</p><p><u>Breast-feeding&nbsp;</u></p><p>It is unknown whether letrozole and its metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded.&nbsp;</p><p>Rozlet is contraindicated during breast-feeding (see section 4.3).&nbsp;</p><p><u>Fertility&nbsp;</u></p><p>The pharmacological action of letrozole is to reduce oestrogen production by aromatase inhibition. In premenopausal women, the inhibition of oestrogen synthesis leads to feedback increases in gonadotropin (LH, FSH) levels. Increased FSH levels in turn stimulate follicular growth, and can induce ovulation.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Rozlet has minor influence on the ability to drive and use machines. Since fatigue and dizziness have been observed with the use of Rozlet and somnolence has been reported uncommonly, caution is advised when driving or using machines.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile&nbsp;</u></p><p>The frequencies of adverse reactions for Rozlet are mainly based on data collected from clinical trials.&nbsp;</p><p>Up to approximately one third of the patients treated with Rozlet in the metastatic setting and approximately 80% of the patients in the adjuvant setting as well as in the extended adjuvant setting experienced adverse reactions. The majority of the adverse reactions occurred during the first few weeks of treatment.&nbsp;</p><p>The most frequently reported adverse reactions in clinical studies were hot flushes, hypercholesterolaemia, arthralgia, fatigue, increased sweating and nausea.&nbsp;</p><p>Important additional adverse reactions that may occur with Rozlet are: skeletal events such as osteoporosis and/or bone fractures and cardiovascular events (including cerebrovascular and thromboembolic events). The frequency category for these adverse reactions is described in Table 1.&nbsp;</p><p><u>Tabulated list of adverse reactions&nbsp;</u></p><p>The frequencies of adverse reactions for Rozlet are mainly based on data collected from clinical trials.&nbsp;</p><p>The following adverse drug reactions, listed in Table 1, were reported from clinical studies and from post-marketing experience with Rozlet:&nbsp;</p><p><strong>Table 1&nbsp;</strong></p><p>Adverse reactions are ranked under headings of frequency, the most frequent first, using the following convention: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).&nbsp;</p><table border="1"><tbody><tr><td colspan="2"><p><strong>Infections and infestations&nbsp;</strong></p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Urinary tract infection&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)&nbsp;</strong></p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Tumour pain1&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Blood and lymphatic system disorders&nbsp;</strong></p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Leukopenia&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Immune system disorders&nbsp;</strong></p></td></tr><tr><td><p>Not known:&nbsp;</p></td><td><p>Anaphylactic reaction&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Metabolism and nutrition disorders&nbsp;</strong></p></td></tr><tr><td><p>Very common:&nbsp;</p></td><td><p>Hypercholesterolaemia&nbsp;</p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Decreased appetite, increased appetite&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Psychiatric disorders&nbsp;</strong></p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Depression&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Anxiety (including nervousness), irritability&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Nervous system disorders&nbsp;</strong></p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Headache, dizziness&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Somnolence, insomnia, memory impairment, dysaesthesia (including paraesthesia, hypoaesthesia), dysgeusia, cerebrovascular accident, carpal tunnel syndrome&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Eye disorders&nbsp;</strong></p></td></tr><tr><td><p>Uncommon&nbsp;</p></td><td><p>Cataract, eye irritation, blurred vision&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Cardiac disorders&nbsp;</strong></p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Palpitations1&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Tachycardia, ischaemic cardiac events (including new or worsening angina, angina requiring surgery, myocardial infarction and myocardial ischaemia)&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Vascular disorders&nbsp;</strong></p></td></tr><tr><td><p>Very common:&nbsp;</p></td><td><p>Hot flushes&nbsp;</p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Hypertension&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Thrombophlebitis (including superficial and deep vein thrombophlebitis)&nbsp;</p></td></tr><tr><td><p>Rare:&nbsp;</p></td><td><p>Pulmonary embolism, arterial thrombosis, cerebral infarction&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Respiratory, thoracic and mediastinal disorders&nbsp;</strong></p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Dyspnoea, cough&nbsp;</p></td></tr><tr><td colspan="2"><p>Gastrointestinal disorders&nbsp;</p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Nausea, dyspepsia1, constipation, abdominal pain, diarrhoea, vomiting&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Dry mouth, stomatitis1&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Hepatobiliary disorders&nbsp;</strong></p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Increased hepatic enzymes, hyperbilirubinemia, jaundice&nbsp;</p></td></tr><tr><td><p>Not known:&nbsp;</p></td><td><p>Hepatitis&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Skin and subcutaneous tissue disorders&nbsp;</strong></p></td></tr><tr><td><p>Very common:&nbsp;</p></td><td><p>Hyperhidrosis&nbsp;</p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Alopecia, rash (including erythematous, maculopapular, psoriaform, and vesicular rash), dry skin&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Pruritus, urticaria&nbsp;</p></td></tr><tr><td><p>Not known:&nbsp;</p></td><td><p>Angioedema, toxic epidermal necrolysis, erythema multiforme&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Musculoskeletal and connective tissue disorders</strong>&nbsp;</p></td></tr><tr><td><p>Very common:&nbsp;</p></td><td><p>Arthralgia&nbsp;</p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Myalgia, bone pain1, osteoporosis, bone fractures, arthritis&nbsp;</p></td></tr><tr><td><p>Not known:&nbsp;</p></td><td><p>Trigger finger&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Renal and urinary disorders&nbsp;</strong></p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Pollakiuria&nbsp;</p></td></tr><tr><td colspan="2"><p>Reproductive system and breast disorders&nbsp;</p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Vaginal haemorrhage&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Vaginal discharge, vulvovaginal dryness, breast pain&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>General disorders and administration site conditions&nbsp;</strong></p></td></tr><tr><td><p>Very common:&nbsp;</p></td><td><p>Fatigue (including asthenia, malaise)&nbsp;</p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Peripheral oedema, chest pain&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>General oedema, mucosal dryness, thirst, pyrexia&nbsp;</p></td></tr><tr><td colspan="2"><p><strong>Investigations&nbsp;</strong></p></td></tr><tr><td><p>Common:&nbsp;</p></td><td><p>Weight increased&nbsp;</p></td></tr><tr><td><p>Uncommon:&nbsp;</p></td><td><p>Weight decreased&nbsp;</p></td></tr></tbody></table><p>1 Adverse drug reactions reported only in the metastatic setting&nbsp;</p><p>Some adverse reactions have been reported with notably different frequencies in the adjuvant treatment setting. The following tables provide information on significant differences in Rozlet versus tamoxifen monotherapy and in the Rozlet-tamoxifen sequential treatment therapy:&nbsp;</p><p><strong>Table 2 Adjuvant Rozlet monotherapy versus tamoxifen monotherapy &ndash; adverse events with significant differences&nbsp;</strong></p><table border="1"><tbody><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>Rozlet, incidence rate&nbsp;</strong></p></td><td colspan="2"><p><strong>Tamoxifen, incidence rate&nbsp;</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p><strong>N=2448&nbsp;</strong></p></td><td colspan="2"><p><strong>N=2447&nbsp;</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>During treatment (Median 5y)&nbsp;</strong></p></td><td><p><strong>Any time after randomization (Median 8y)&nbsp;</strong></p></td><td><p><strong>During treatment (Median 5y)&nbsp;</strong></p></td><td><p><strong>Any time after randomization (Median 8y)&nbsp;</strong></p></td></tr><tr><td><p>Bone fracture&nbsp;</p></td><td><p>10.2%&nbsp;</p></td><td><p>14.7%&nbsp;</p></td><td><p>7.2%&nbsp;</p></td><td><p>11.4%&nbsp;</p></td></tr><tr><td><p>Osteoporosis&nbsp;</p></td><td><p>5.1%&nbsp;</p></td><td><p>5.1%&nbsp;</p></td><td><p>2.7%&nbsp;</p></td><td><p>2.7%&nbsp;</p></td></tr><tr><td><p>Thromboembolic events&nbsp;</p></td><td><p>2.1%&nbsp;</p></td><td><p>3.2%&nbsp;</p></td><td><p>3.6%&nbsp;</p></td><td><p>4.6%&nbsp;</p></td></tr><tr><td><p>Myocardial infarction&nbsp;</p></td><td><p>1.0%&nbsp;</p></td><td><p>1.7%&nbsp;</p></td><td><p>0.5%&nbsp;</p></td><td><p>1.1%&nbsp;</p></td></tr><tr><td><p>Endometrial hyperplasia / endometrial cancer&nbsp;</p></td><td><p>0.2%&nbsp;</p></td><td><p>0.4%&nbsp;</p></td><td><p>2.3%&nbsp;</p></td><td><p>2.9%&nbsp;</p></td></tr><tr><td colspan="5"><p>Note: &ldquo;During treatment&rdquo; includes 30 days after last dose. &ldquo;Any time&rdquo; includes follow-up period after completion or discontinuation of study treatment.&nbsp;</p><p>Differences were based on risk ratios and 95% confidence intervals.&nbsp;</p></td></tr></tbody></table><p><strong>Table 3 Sequential treatment versus Rozlet monotherapy &ndash; adverse events with significant differences&nbsp;</strong></p><table border="1"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Rozlet monotherapy&nbsp;</strong></p></td><td><p><strong>Rozlet-&gt;tamoxifen&nbsp;</strong></p></td><td><p><strong>Tamoxifen-&gt;Rozlet&nbsp;</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>N=1535&nbsp;</strong></p></td><td><p><strong>N=1527&nbsp;</strong></p></td><td><p><strong>N=1541&nbsp;</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>5 years&nbsp;</strong></p></td><td><p><strong>2 yrs-&gt; 3 yrs&nbsp;</strong></p></td><td><p><strong>2 yrs-&gt; 3 yrs&nbsp;</strong></p></td></tr><tr><td><p>Bone fractures&nbsp;</p></td><td><p>10.0%&nbsp;</p></td><td><p>7.7%*&nbsp;</p></td><td><p>9.7%&nbsp;</p></td></tr><tr><td><p>Endometrial proliferative disorders&nbsp;</p></td><td><p>0.7%&nbsp;</p></td><td><p>3.4%**&nbsp;</p></td><td><p>1.7%**&nbsp;</p></td></tr><tr><td><p>Hypercholesterolaemia&nbsp;</p></td><td><p>52.5%&nbsp;</p></td><td><p>44.2%*&nbsp;</p></td><td><p>40.8%*&nbsp;</p></td></tr><tr><td><p>Hot flushes&nbsp;</p></td><td><p>37.6%&nbsp;</p></td><td><p>41.7%**&nbsp;</p></td><td><p>43.9%**&nbsp;</p></td></tr><tr><td><p>Vaginal bleeding&nbsp;</p></td><td><p>6.3%&nbsp;</p></td><td><p>9.6%**&nbsp;</p></td><td><p>12.7%**&nbsp;</p></td></tr><tr><td colspan="4"><p>* Significantly less than with Rozlet monotherapy&nbsp;</p><p>** Significantly more than with Rozlet monotherapy&nbsp;</p><p>Note : Reporting period is during treatment or within 30 days of stopping treatment&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Description of selected adverse reactions&nbsp;</u></p><p><em>Cardiac adverse reactions</em></p><p>reactions&nbsp;he adjuvant setting, in addition to the data presented in Table 2, the following adverse events were reported for Rozlet and tamoxifen, respectively (at median treatment duration of 60 months plus 30 days): angina requiring surgery (1.0% vs. 1.0%); cardiac failure (1.1% vs. 0.6%); hypertension (5.6% vs. 5.7%); cerebrovascular accident/transient ischaemic attack (2.1% vs. 1.9%).&nbsp;</p><p>In the extended adjuvant setting for Rozlet (median duration of treatment 5 years) and placebo (median duration of treatment 3 years), respectively: angina requiring surgery (0.8% vs. 0.6%); new or worsening angina (1.4% vs. 1.0%); myocardial infarction (1.0% vs. 0.7%); thromboembolic event* (0.9% vs. 0.3%); stroke/transient ischaemic attack* (1.5% vs. 0.8%) were reported.&nbsp;</p><p>Events marked * were statistically significantly different in the two treatment arms.&nbsp;</p><p><em>Skeletal adverse reactions</em></p><p>For skeletal safety data from the adjuvant setting, please refer to Table 2.&nbsp;</p><p>In the extended adjuvant setting, significantly more patients treated with Rozlet experienced bone fractures or osteoporosis (bone fractures, 10.4% and osteoporosis, 12.2%) than patients in the placebo arm (5.8% and 6.4%, respectively). Median duration of treatment was 5 years for Rozlet, compared with 3 years for placebo.&nbsp;</p><p><u>Reporting of suspected adverse reactions&nbsp;&nbsp;</u></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system</p><p>&nbsp;</p><table border="1" align="center" cellspacing="1" cellpadding="1"><tbody><tr><td><p><strong>&nbsp;To report any side effect(s) :</strong>&nbsp;</p><p><strong>For Saudi Arabia :&nbsp;</strong></p><p>The National Pharmacovigilance and Drug Safety Center ( NPC)&nbsp;</p><ul><li>Fax : +966-11-205-7662&nbsp;</li><li>Call NPC at +966-11-2038222 , Exts : 2317-2356-2340</li><li>Reporting hotline : 19999.</li><li>E-mail : npc.drug@sfda.gov.sa</li><li>Website : www.sfda.gov.sa/npc</li></ul></td></tr></tbody></table><p>&nbsp;</p><p><strong>For UAE:&nbsp;</strong></p><p>Pharmacovigilance &amp; Medical Device section&nbsp;<br />P.O.Box: 1853 &nbsp;</p><p>Tel: 80011111&nbsp;</p><p>Email: pv@moh.gov.ae&nbsp;</p><p>Drug Department&nbsp;<br />Ministry of Health &amp; Prevention&nbsp;<br />Dubai&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Isolated cases of overdose with Rozlet have been reported.&nbsp;</p><p>No specific treatment for overdose is known; treatment should be symptomatic and supportive.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Endocrine therapy. Hormone antagonist and related agents: aromatase inhibitor, ATC code: L02BG04.&nbsp;</p><p><u>Pharmacodynamic effects&nbsp;</u></p><p>The elimination of oestrogen-mediated growth stimulation is a prerequisite for tumour response in cases where the growth of tumour tissue depends on the presence of oestrogens and endocrine therapy is used. In postmenopausal women, oestrogens are mainly derived from the action of the aromatase enzyme, which converts adrenal androgens - primarily androstenedione and testosterone - to oestrone and oestradiol. The suppression of oestrogen biosynthesis in peripheral tissues and the cancer tissue itself can therefore be achieved by specifically inhibiting the aromatase enzyme.&nbsp;</p><p>Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitively binding to the haem of the aromatase cytochrome P450, resulting in a reduction of oestrogen biosynthesis in all tissues where present.&nbsp;</p><p>In healthy postmenopausal women, single doses of 0.1 mg, 0.5 mg, and 2.5 mg letrozole suppress serum oestrone and oestradiol by 75%, 78% and 78% from baseline respectively. Maximum suppression is achieved in 48-78 hours.&nbsp;</p><p>In postmenopausal patients with advanced breast cancer, daily doses of 0.1 mg to 5 mg suppressed plasma concentration of oestradiol, oestrone, and oestrone sulphate by 75-95% from baseline in all patients treated. With doses of 0.5 mg and higher, many values of oestrone and oestrone sulphate were below the limit of detection in the assays, indicating that higher oestrogen suppression is achieved with these doses. Oestrogen suppression was maintained throughout treatment in all these patients.&nbsp;</p><p>Letrozole is highly specific in inhibiting aromatase activity. Impairment of adrenal steroidogenesis has not been observed. No clinically relevant changes were found in the plasma concentrations of cortisol, aldosterone, 11-deoxycortisol, 17-hydroxyprogesterone, and ACTH or in plasma renin activity among postmenopausal patients treated with a daily dose of letrozole 0.1 to 5 mg. The ACTH stimulation test performed after 6 and 12 weeks of treatment with daily doses of 0.1 mg, 0.25 mg, 0.5 mg, 1 mg, 2.5 mg, and 5 mg did not indicate any attenuation of aldosterone or cortisol production. Thus, glucocorticoid and mineralocorticoid supplementation is not necessary.&nbsp;</p><p>No changes were noted in plasma concentrations of androgens (androstenedione and testosterone) among healthy postmenopausal women after 0.1 mg, 0.5 mg, and 2.5 mg single doses of letrozole or in plasma concentrations of androstenedione among postmenopausal patients treated with daily doses of 0.1 mg to 5 mg, indicating that the blockade of oestrogen biosynthesis does not lead to accumulation of androgenic precursors. Plasma levels of LH and FSH are not affected by letrozole in patients, nor is thyroid function as evaluated by TSH, T4, and T3 uptake test.&nbsp;</p><p><u>Adjuvant treatment&nbsp;</u></p><p><em><u>Study BIG 1-98&nbsp;</u></em></p><p>BIG 1-98 was a multicentre, double-blind study in which over 8,000 postmenopausal women with hormone receptor-positive early breast cancer were randomised to one of the following treatments: A. tamoxifen for 5 years; B. Rozlet for 5 years; C. tamoxifen for 2 years followed by Rozlet for 3 years; D. Rozlet for 2 years followed by tamoxifen for 3 years.&nbsp;</p><p>The primary endpoint was disease-free survival (DFS); secondary efficacy endpoints were time to distant metastasis (TDM), distant disease-free survival (DDFS), overall survival (OS), systemic disease-free survival (SDFS), invasive contralateral breast cancer and time to breast cancer recurrence.&nbsp;</p><p><em>Efficacy results at a median follow-up of 26 and 60 months&nbsp;</em></p><p>Data in Table 4 reflect the results of the Primary Core Analysis (PCA) based on data from the monotherapy arms (A and B) and from the two switching arms (C and D) at a median treatment duration of 24 months and a median follow-up of 26 months and at a median treatment duration of 32 months and a median follow-up of 60 months.&nbsp;</p><p>The 5-year DFS rates were 84% for Rozlet and 81.4% for tamoxifen.&nbsp;</p><p><strong>Table 4 Primary Core Analysis: Disease-free and overall survival, at a median follow-up of 26 months and at median follow-up of 60 months (ITT population)&nbsp;</strong></p><table border="1"><tbody><tr><td><p>&nbsp;</p></td><td colspan="6"><p><strong>Primary Core Analysis&nbsp;</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="3"><p><strong>Median follow-up 26 months&nbsp;</strong></p></td><td colspan="3"><p><strong>Median follow-up 60 months&nbsp;</strong></p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Rozlet&nbsp;</strong></p><p><strong>N=4003&nbsp;</strong></p></td><td><p><strong>Tamoxifen&nbsp;</strong></p><p><strong>N=4007&nbsp;</strong></p></td><td><p><strong>HR1&nbsp;</strong></p><p><strong>(95% CI)&nbsp;</strong></p><p><strong>P&nbsp;</strong></p></td><td><p><strong>Rozlet&nbsp;</strong></p><p><strong>N=4003&nbsp;</strong></p></td><td><p><strong>Tamoxifen&nbsp;</strong></p><p><strong>N=4007&nbsp;</strong></p></td><td><p><strong>HR1&nbsp;</strong></p><p><strong>(95% CI)&nbsp;</strong></p><p><strong>P&nbsp;</strong></p></td></tr><tr><td><p>Disease-free survival (primary) - events (protocol definition2)&nbsp;</p></td><td><p>351&nbsp;</p></td><td><p>428&nbsp;</p></td><td><p>0.81&nbsp;</p><p>(0.70, 0.93)&nbsp;</p><p>0.003&nbsp;</p></td><td><p>585&nbsp;</p></td><td><p>664&nbsp;</p></td><td><p>0.86&nbsp;</p><p>(0.77, 0.96)&nbsp;</p><p>0.008&nbsp;</p></td></tr><tr><td><p>Overall survival (secondary)&nbsp;</p><p>Number of deaths&nbsp;</p></td><td><p>166&nbsp;</p></td><td><p>192&nbsp;</p></td><td><p>0.86&nbsp;</p><p>(0.70, 1.06)&nbsp;</p></td><td><p>330&nbsp;</p></td><td><p>374&nbsp;</p></td><td><p>0.87&nbsp;</p><p>(0.75, 1.01)&nbsp;</p></td></tr><tr><td colspan="7"><p>HR = Hazard ratio; CI = Confidence interval&nbsp;</p><p>1 Log rank test, stratified by randomisation option and use of chemotherapy (yes/no)&nbsp;</p><p>2 DFS events: loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, second (non-breast) primary malignancy, death from any cause without a prior cancer event.&nbsp;</p></td></tr></tbody></table><p><em>Results at a median follow-up of 96 months (monotherapy arms only)&nbsp;</em></p><p>The Monotherapy Arms Analysis (MAA) long-term update of the efficacy of Rozlet monotherapy compared to tamoxifen monotherapy (median duration of adjuvant treatment: 5 years) is presented in Table 5.&nbsp;</p><p><strong>Table 5 Monotherapy Arms Analysis: Disease-free and overall survival at a median follow-up of 96 months (ITT population)&nbsp;</strong></p><table border="1"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Rozlet&nbsp;</strong></p><p><strong>N=2463&nbsp;</strong></p></td><td><p><strong>Tamoxifen&nbsp;</strong></p><p><strong>N=2459&nbsp;</strong></p></td><td><p><strong>Hazard Ratio1&nbsp;</strong></p><p><strong>(95% CI)&nbsp;</strong></p></td><td><p><strong>P Value&nbsp;</strong></p></td></tr><tr><td><p>Disease-free survival events (primary) 2&nbsp;</p></td><td><p>626&nbsp;</p></td><td><p>698&nbsp;</p></td><td><p>0.87 (0.78, 0.97)&nbsp;</p></td><td><p>0.01&nbsp;</p></td></tr><tr><td><p>Time to distant metastasis (secondary)&nbsp;</p></td><td><p>301&nbsp;</p></td><td><p>342&nbsp;</p></td><td><p>0.86 (0.74, 1.01)&nbsp;</p></td><td><p>0.06&nbsp;</p></td></tr><tr><td><p>Overall survival (secondary) - deaths&nbsp;</p></td><td><p>393&nbsp;</p></td><td><p>436&nbsp;</p></td><td><p>0.89 (0.77, 1.02)&nbsp;</p></td><td><p>0.08&nbsp;</p></td></tr><tr><td><p>Censored analysis of DFS3&nbsp;</p></td><td><p>626&nbsp;</p></td><td><p>649&nbsp;</p></td><td><p>0.83 (0.74, 0.92)&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Censored analysis of OS3&nbsp;</p></td><td><p>393&nbsp;</p></td><td><p>419&nbsp;</p></td><td><p>0.81 (0.70, 0.93)&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="5"><p>1 Log rank test, stratified by randomisation option and use of chemotherapy (yes/no)&nbsp;</p><p>2 DFS events: loco-regional recurrence, distant metastasis, invasive contralateral breast cancer, second (non-breast) primary malignancy, death from any cause without a prior cancer event.&nbsp;</p><p>3 Observations in the tamoxifen arm censored at the date of selectively switching to letrozole&nbsp;</p></td></tr></tbody></table><p><em>Sequential Treatments Analysis (STA)&nbsp;</em></p><p>The Sequential Treatments Analysis (STA) addresses the second primary question of BIG 1-98, namely whether sequencing of tamoxifen and letrozole would be superior to monotherapy. There were no significant differences in DFS, OS, SDFS, or DDFS from switch with respect to monotherapy (Table 6).&nbsp;</p><p><strong>Table 6 Sequential treatments analysis of disease-free survival with letrozole as initial endocrine agent (STA switch population)&nbsp;</strong></p><table border="1"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>N&nbsp;</strong></p></td><td><p><strong>Number of events1&nbsp;</strong></p></td><td><p><strong>Hazard ratio2&nbsp;</strong></p></td><td><p><strong>(97.5% confidence interval)&nbsp;</strong></p></td><td><p><strong>Cox model P-value&nbsp;</strong></p></td></tr><tr><td><p>[Letrozole&rarr;]Tamoxifen&nbsp;</p></td><td><p><strong>1460&nbsp;</strong></p></td><td><p><strong>254&nbsp;</strong></p></td><td><p><strong>1.03&nbsp;</strong></p></td><td><p><strong>(0.84, 1.26)&nbsp;</strong></p></td><td><p><strong>0.72&nbsp;</strong></p></td></tr><tr><td><p>Letrozole&nbsp;</p></td><td><p><strong>1464&nbsp;</strong></p></td><td><p><strong>249&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="6"><p>1 Protocol definition, including second non-breast primary malignancies, after switch / beyond two years&nbsp;</p><p>2 Adjusted by chemotherapy use&nbsp;</p></td></tr></tbody></table><p>There were no significant differences in DFS, OS, SDFS or DDFS in any of the STA from randomisation pairwise comparisons (Table 7).&nbsp;</p><p><strong>Table 7 Sequential Treatments Analyses from randomisation (STA-R) of disease-free survival (ITT STA-R population)&nbsp;</strong></p><table border="1"><tbody><tr><td><p>&nbsp;</p></td><td><p><strong>Letrozole&rarr;Tamoxifen&nbsp;</strong></p></td><td><p><strong>Letrozole&nbsp;</strong></p></td></tr><tr><td><p>Number of patients&nbsp;</p></td><td><p>1540&nbsp;</p></td><td><p>1546&nbsp;</p></td></tr><tr><td><p>Number of patients with DFS events (protocol definition)&nbsp;</p></td><td><p>330&nbsp;</p></td><td><p>319&nbsp;</p></td></tr><tr><td><p>Hazard ratio1 (99% CI)&nbsp;</p></td><td colspan="2"><p>1.04 (0.85, 1.27)&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p><strong>Letrozole&rarr;Tamoxifen&nbsp;</strong></p></td><td><p><strong>Tamoxifen2&nbsp;</strong></p></td></tr><tr><td><p>Number of patients&nbsp;</p></td><td><p>1540&nbsp;</p></td><td><p>1548&nbsp;</p></td></tr><tr><td><p>Number of patients with DFS events (protocol definition)&nbsp;</p></td><td><p>330&nbsp;</p></td><td><p>353&nbsp;</p></td></tr><tr><td><p>Hazard ratio1 (99% CI)&nbsp;</p></td><td colspan="2"><p>0.92 (0.75, 1.12)&nbsp;</p></td></tr><tr><td colspan="3"><p>1 Adjusted by chemotherapy use (yes/no)&nbsp;</p><p>2 626 (40%) patients selectively crossed to letrozole after tamoxifen arm unblinded in 2005&nbsp;</p></td></tr></tbody></table><p><u><em>Study D2407&nbsp;</em></u></p><p>Study D2407 is an open-label, randomised, multicentre post approval safety study designed to compare the effects of adjuvant treatment with letrozole and tamoxifen on bone mineral density (BMD) and serum lipid profiles. A total of 262 patients were assigned either letrozole for 5 years or tamoxifen for 2 years followed by letrozole for 3 years.&nbsp;</p><p>At 24 months there was a statistically significant difference in the primary end-point; the lumbar spine BMD (L2-L4) showed a median decrease of 4.1% for letrozole compared to a median increase of 0.3% for tamoxifen.&nbsp;</p><p>No patient with a normal BMD at baseline became osteoporotic during 2 years of treatment and only 1 patient with osteopenia at baseline (T score of -1.9) developed osteoporosis during the treatment period (assessment by central review).&nbsp;</p><p>The results for total hip BMD were similar to those for lumbar spine but less pronounced.&nbsp;</p><p>There was no significant difference between treatments in the rate of fractures &ndash; 15% in the letrozole arm, 17% in the tamoxifen arm.&nbsp;</p><p>Median total cholesterol levels in the tamoxifen arm were decreased by 16% after 6 months compared to baseline and this decrease was maintained at subsequent visits up to 24 months. In the letrozole arm, total cholesterol levels were relatively stable over time, giving a statistically significant difference in favour of tamoxifen at each time point.&nbsp;</p><p><u><em>Extended adjuvant treatment (MA-17)&nbsp;</em></u></p><p>In a multicentre, double-blind, randomised, placebo-controlled study (MA-17), over 5,100 postmenopausal women with receptor-positive or unknown primary breast cancer who had completed adjuvant treatment with tamoxifen (4.5 to 6 years) were randomised to either Rozlet or placebo for 5 years.&nbsp;</p><p>The primary endpoint was disease-free survival, defined as the interval between randomisation and the earliest occurrence of loco-regional recurrence, distant metastasis, or contralateral breast cancer.&nbsp;</p><p>The first planned interim analysis at a median follow-up of around 28 months (25% of patients being followed up for at least 38 months), showed that Rozlet significantly reduced the risk of breast cancer recurrence by 42% compared with placebo (HR 0.58; 95% CI 0.45, 0.76; P=0.00003). The benefit in favour of letrozole was observed regardless of nodal status. There was no significant difference in overall survival: (Rozlet 51 deaths; placebo 62; HR 0.82; 95% CI 0.56, 1.19).&nbsp;</p><p>Consequently, after the first interim analysis the study was unblinded and continued in an open-label fashion and patients in the placebo arm were allowed to switch to Rozlet for up to 5 years. Over 60% of eligible patients (disease-free at unblinding) opted to switch to Rozlet. The final analysis included 1,551 women who switched from placebo to Rozlet at a median of 31 months (range 12 to 106 months) after completion of tamoxifen adjuvant therapy. Median duration for Rozlet after switch was 40 months.&nbsp;</p><p>The final analysis conducted at a median follow-up of 62 months confirmed the significant reduction in the risk of breast cancer recurrence with Rozlet.&nbsp;</p><p><strong>Table 8 Disease-free and overall survival (Modified ITT population)&nbsp;</strong></p><table border="1"><tbody><tr><td><p>&nbsp;</p></td><td colspan="3"><p>Median follow-up 28 months1&nbsp;</p></td><td colspan="3"><p>Median follow-up 62 months&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Letrozole&nbsp;</p><p>N=2582&nbsp;</p></td><td><p>Placebo&nbsp;</p><p>N=2586&nbsp;</p></td><td><p>HR (95% CI)2&nbsp;</p><p>P value&nbsp;</p></td><td><p>Letrozole&nbsp;</p><p>N=2582&nbsp;</p></td><td><p>Placebo&nbsp;</p><p>N=2586&nbsp;</p></td><td><p>HR (95% CI)2&nbsp;</p><p>P value&nbsp;</p></td></tr><tr><td><p><strong>Disease-free survival3&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Events&nbsp;</p></td><td><p>92 (3.6%)&nbsp;</p></td><td><p>155 (6.0%)&nbsp;</p></td><td><p>0.58&nbsp;</p><p>(0.45, 0.76)&nbsp;</p><p>0.00003&nbsp;</p></td><td><p>209 (8.1%)&nbsp;</p></td><td><p>286 (11.1%)&nbsp;</p></td><td><p>0.75&nbsp;</p><p>(0.63, 0.89)&nbsp;</p></td></tr><tr><td><p>4-year DFS rate&nbsp;</p></td><td><p>94.4%&nbsp;</p></td><td><p>89.8%&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>94.4%&nbsp;</p></td><td><p>91.4%&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td colspan="7"><p><strong>Disease-free survival3, including deaths from any cause&nbsp;</strong></p></td></tr><tr><td><p>Events&nbsp;</p></td><td><p>122 (4.7%)&nbsp;</p></td><td><p>193 (7.5%)&nbsp;</p></td><td><p>0.62&nbsp;</p><p>(0.49, 0.78)&nbsp;</p></td><td><p>344 (13.3%)&nbsp;</p></td><td><p>402 (15.5%)&nbsp;</p></td><td><p>0.89&nbsp;</p><p>(0.77, 1.03)&nbsp;</p></td></tr><tr><td><p>5 year DFS rate&nbsp;</p></td><td><p>90.5%&nbsp;</p></td><td><p>80.8%&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>88.8%&nbsp;</p></td><td><p>86.7%&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Distant metastases&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Events&nbsp;</p></td><td><p>57 (2.2%)&nbsp;</p></td><td><p>93 (3.6%)&nbsp;</p></td><td><p>0.61&nbsp;</p><p>(0.44, 0.84)&nbsp;</p></td><td><p>142&nbsp;</p><p>(5.5%)&nbsp;</p></td><td><p>169&nbsp;</p><p>(6.5%)&nbsp;</p></td><td><p>0.88&nbsp;</p><p>(0.70, 1.10)&nbsp;</p></td></tr><tr><td><p><strong>Overall survival&nbsp;</strong></p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Deaths&nbsp;</p></td><td><p>51 (2.0%)&nbsp;</p></td><td><p>62 (2.4%)&nbsp;</p></td><td><p>0.82&nbsp;</p><p>(0.56, 1.19)&nbsp;</p></td><td><p>236 (9.1%)&nbsp;</p></td><td><p>232 (9.0%)&nbsp;</p></td><td><p>1.13&nbsp;</p><p>(0.95, 1.36)&nbsp;</p></td></tr><tr><td><p>Deaths4&nbsp;</p></td><td><p>- -&nbsp;</p></td><td><p>- -&nbsp;</p></td><td><p>- -&nbsp;</p></td><td><p>2365 (9.1%)&nbsp;</p></td><td><p>1706 (6.6%)&nbsp;</p></td><td><p>0.78&nbsp;</p><p>(0.64, 0.96)&nbsp;</p></td></tr><tr><td colspan="7"><p>HR = Hazard ratio; CI = Confidence Interval&nbsp;</p><p>1 When the study was unblinded in 2003, 1551 patients in the randomised placebo arm (60% of those eligible to switch &ndash; i.e. who were disease-free) switched to letrozole at a median 31 months after randomisation. The analyses presented here ignore the selective crossover.&nbsp;</p><p>2 Stratified by receptor status, nodal status and prior adjuvant chemotherapy.&nbsp;</p><p>3 Protocol definition of disease-free survival events: loco-regional recurrence, distant metastasis or contralateral breast cancer.&nbsp;</p><p>4 Exploratory analysis, censoring follow-up times at the date of switch (if it occurred) in the placebo arm.&nbsp;</p><p>5 Median follow-up 62 months.&nbsp;</p><p>6 Median follow-up until switch (if it occurred) 37 months.&nbsp;</p></td></tr></tbody></table><p>In the MA-17 bone substudy in which concomitant calcium and vitamin D were given, greater decreases in BMD compared to baseline occurred with Rozlet compared with placebo. The only statistically significant difference occurred at 2 years and was in total hip BMD (letrozole median decrease of 3.8% vs placebo median decrease of 2.0%).&nbsp;</p><p>In the MA-17 lipid substudy there were no significant differences between letrozole and placebo in total cholesterol or in any lipid fraction.&nbsp;</p><p>In the updated quality of life substudy there were no significant differences between treatments in physical component summary score or mental component summary score, or in any domain score in the SF-36 scale. In the MENQOL scale, significantly more women in the Rozlet arm than in the placebo arm were most bothered (generally in the first year of treatment) by those symptoms deriving from oestrogen deprivation &ndash; hot flushes and vaginal dryness. The symptom that bothered most patients in both treatment arms was aching muscles, with a statistically significant difference in favour of placebo.&nbsp;</p><p><u><em>Neoadjuvant treatment&nbsp;</em></u></p><p>A double blind trial (P024) was conducted in 337 postmenopausal breast cancer patients randomly allocated either Rozlet 2.5 mg for 4 months or tamoxifen for 4 months. At baseline all patients had tumours stage T2-T4c, N0-2, M0, ER and/or PgR positive and none of the patients would have qualified for breast-conserving surgery. Based on clinical assessment there were 55% objective responses in the Rozlet arm versus 36% for the tamoxifen arm (P&lt;0.001). This finding was consistently confirmed by ultrasound (Rozlet 35% vs tamoxifen 25%, P=0.04) and mammography (Rozlet 34% vs tamoxifen 16%, P&lt;0.001). In total 45% of patients in the Rozlet group versus 35% of patients in the tamoxifen group (P=0.02) underwent breast-conserving therapy). During the 4-month pre-operative treatment period, 12% of patients treated with Rozlet and 17% of patients treated with tamoxifen had disease progression on clinical assessment.&nbsp;</p><p><u><em>First-line treatment&nbsp;</em></u></p><p>One controlled double-blind trial was conducted comparing Rozlet (letrozole) 2.5 mg to tamoxifen 20 mg as first-line therapy in postmenopausal women with advanced breast cancer. In 907 women, letrozole was superior to tamoxifen in time to progression (primary endpoint) and in overall objective response, time to treatment failure and clinical benefit.&nbsp;</p><p>The results are summarised in Table 9:&nbsp;</p><p><strong>Table 9 Results at a median follow-up of 32 months&nbsp;</strong></p><table border="1"><tbody><tr><td><p><strong>Variable&nbsp;</strong></p></td><td><p><strong>Statistic&nbsp;</strong></p></td><td><p><strong>Rozlet&nbsp;</strong></p><p><strong>N=453&nbsp;</strong></p></td><td><p><strong>Tamoxifen&nbsp;</strong></p><p><strong>N=454&nbsp;</strong></p></td></tr><tr><td rowspan="5" colspan="1"><p><strong>Time to progression&nbsp;</strong></p></td><td><p>Median&nbsp;</p></td><td><p>9.4 months&nbsp;</p></td><td><p>6.0 months&nbsp;</p></td></tr><tr><td><p>(95% CI for median)&nbsp;</p></td><td><p>(8.9, 11.6 months)&nbsp;</p></td><td><p>(5.4, 6.3 months)&nbsp;</p></td></tr><tr><td><p>Hazard ratio (HR)&nbsp;</p></td><td colspan="2"><p>0.72&nbsp;</p></td></tr><tr><td><p>(95% CI for HR)&nbsp;</p></td><td colspan="2"><p>(0.62, 0.83)&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>P&lt;0.0001&nbsp;</p></td></tr><tr><td rowspan="5" colspan="1"><p><strong>Objective response rate (ORR)&nbsp;</strong></p></td><td><p>CR+PR&nbsp;</p></td><td><p>145 (32%)&nbsp;</p></td><td><p>95 (21%)&nbsp;</p></td></tr><tr><td><p>(95% CI for rate)&nbsp;</p></td><td><p>(28, 36%)&nbsp;</p></td><td><p>(17, 25%)&nbsp;</p></td></tr><tr><td><p>Odds ratio&nbsp;</p></td><td colspan="2"><p>1.78&nbsp;</p></td></tr><tr><td><p>(95% CI for odds ratio)&nbsp;</p></td><td colspan="2"><p>(1.32, 2.40)&nbsp;</p></td></tr><tr><td><p>&nbsp;</p></td><td colspan="2"><p>P=0.0002&nbsp;</p></td></tr></tbody></table><p>Time to progression was significantly longer, and response rate significantly higher for letrozole irrespective of whether adjuvant anti-oestrogen therapy had been given or not. Time to progression was significantly longer for letrozole irrespective of dominant site of disease. Median time to progression was 12.1 months for Rozlet and 6.4 months for tamoxifen in patients with soft tissue disease only and median 8.3 months for Rozlet and 4.6 months for tamoxifen in patients with visceral metastases.&nbsp;</p><p>Study design allowed patients to cross over upon progression to the other therapy or discontinue from the study. Approximately 50% of patients crossed over to the opposite treatment arm and crossover was virtually completed by 36 months. The median time to crossover was 17 months (Rozlet to tamoxifen) and 13 months (tamoxifen to Rozlet).&nbsp;</p><p>Rozlet treatment in the first-line therapy of advanced breast cancer resulted in a median overall survival of 34 months compared with 30 months for tamoxifen (logrank test P=0.53, not significant). The absence of an advantage for Rozlet on overall survival could be explained by the crossover design of the study.&nbsp;</p><p><u><em>Second-line treatment&nbsp;</em></u></p><p>Two well-controlled clinical trials were conducted comparing two letrozole doses (0.5 mg and 2.5 mg) to megestrol acetate and to aminoglutethimide, respectively, in postmenopausal women with advanced breast cancer previously treated with anti-oestrogens.&nbsp;</p><p>Time to progression was not significantly different between letrozole 2.5 mg and megestrol acetate (P=0.07). Statistically significant differences were observed in favour of letrozole 2.5 mg compared to megestrol acetate in overall objective tumour response rate (24% vs 16%, P=0.04), and in time to treatment failure (P=0.04). Overall survival was not significantly different between the 2 arms (P=0.2).&nbsp;</p><p>In the second study, the response rate was not significantly different between letrozole 2.5 mg and aminoglutethimide (P=0.06). Letrozole 2.5 mg was statistically superior to aminoglutethimide for time to progression (P=0.008), time to treatment failure (P=0.003) and overall survival (P=0.002).&nbsp;</p><p><u>Male breast cancer&nbsp;</u></p><p>Use of Rozlet in men with breast cancer has not been studied.&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption&nbsp;</u></p><p>Letrozole is rapidly and completely absorbed from the gastrointestinal tract (mean absolute bioavailability: 99.9%). Food slightly decreases the rate of absorption (median tmax 1 hour fasted versus 2 hours fed; and mean Cmax 129 &plusmn; 20.3 nmol/litre fasted versus 98.7 &plusmn; 18.6 nmol/litre fed) but the extent of absorption (AUC) is not changed. The minor effect on the absorption rate is not considered to be of clinical relevance, and therefore letrozole may be taken without regard to mealtimes.&nbsp;</p><p><u>Distribution&nbsp;</u></p><p>Plasma protein binding of letrozole is approximately 60%, mainly to albumin (55%). The concentration of letrozole in erythrocytes is about 80% of that in plasma. After administration of 2.5 mg 14C-labelled letrozole, approximately 82% of the radioactivity in plasma was unchanged compound. Systemic exposure to metabolites is therefore low. Letrozole is rapidly and extensively distributed to tissues. Its apparent volume of distribution at steady state is about 1.87 &plusmn; 0.47 l/kg.&nbsp;</p><p><u>Biotransformation&nbsp;</u></p><p>Metabolic clearance to a pharmacologically inactive carbinol metabolite is the major elimination pathway of letrozole (CLm = 2.1 l/h) but is relatively slow when compared to hepatic blood flow (about 90 l/h). The cytochrome P450 isoenzymes 3A4 and 2A6 were found to be capable of converting letrozole to this metabolite. Formation of minor unidentified metabolites and direct renal and faecal excretion play only a minor role in the overall elimination of letrozole. Within 2 weeks after administration of 2.5 mg 14C-labelled letrozole to healthy postmenopausal volunteers, 88.2 &plusmn; 7.6% of the radioactivity was recovered in urine and 3.8 &plusmn; 0.9% in faeces. At least 75% of the radioactivity recovered in urine up to 216 hours (84.7 &plusmn; 7.8% of the dose) was attributed to the glucuronide of the carbinol metabolite, about 9% to two unidentified metabolites, and 6% to unchanged letrozole.&nbsp;</p><p><u>Elimination&nbsp;</u></p><p>The apparent terminal elimination half-life in plasma is about 2 to 4 days. After daily administration of 2.5 mg steady-state levels are reached within 2 to 6 weeks. Plasma concentrations at steady state are approximately 7 times higher than concentrations measured after a single dose of 2.5 mg, while they are 1.5 to 2 times higher than the steady-state values predicted from the concentrations measured after a single dose, indicating a slight non-linearity in the pharmacokinetics of letrozole upon daily administration of 2.5 mg. Since steady-state levels are maintained over time, it can be concluded that no continuous accumulation of letrozole occurs.&nbsp;</p><p><u>Linearity/non-linearity&nbsp;</u></p><p>The pharmacokinetics of letrozole were dose proportional after single oral doses up to 10 mg (dose range: 0.01 to 30 mg) and after daily doses up to 1.0 mg (dose range: 0.1 to 5mg). After a 30 mg single oral dose there was a slightly dose over-proportional increase in AUC value. The dose over-proportionality is likely to be the result of a saturation of metabolic elimination processes. Steady levels were reached after 1 to 2 months at all dosage regimens tested (0.1-5.0 mg daily).&nbsp;</p><p><u>Special populations&nbsp;</u></p><p><em>Elderly&nbsp;</em></p><p>Age had no effect on the pharmacokinetics of letrozole.&nbsp;</p><p><em>Renal impairment&nbsp;</em></p><p>In a study involving 19 volunteers with varying degrees of renal function (24-hour creatinine clearance 9-116 ml/min) no effect on the pharmacokinetics of letrozole was found after a single dose of 2.5 mg. In addition to the above study assessing the influence of renal impairment on letrozole, a covariate analysis was performed on the data of two pivotal studies (Study AR/BC2 and Study AR/BC3). Calculated creatinine clearance (CLcr) [Study AR/BC2 range: 19 to 187 mL/min; Study AR/BC3 range: 10 to 180 mL/min] showed no statistically significant association between letrozole plasma trough levels at steady-state (Cmin). Futhermore, data of Study AR/BC2 and Study AR/BC3 in second-line metastatic breast cancer showed no evidence of an adverse effect of letrozole on CLcr or an impairment of renal function.&nbsp;</p><p>Therefore, no dose adjustment is required for patients with renal impairment (CLcr &ge;10 mL/min). Little information is available in patients with severe impairment of renal function (CLcr &lt;10 mL/min).&nbsp;</p><p><em>Hepatic impairment&nbsp;</em></p><p>In a similar study involving subjects with varying degrees of hepatic function, the mean AUC values of the volunteers with moderate hepatic impairment (Child-Pugh B) was 37% higher than in normal subjects, but still within the range seen in subjects without impaired function. In a study comparing the pharmacokinetics of letrozole after a single oral dose in eight male subjects with liver cirrhosis and severe hepatic impairment (Child-Pugh C) to those in healthy volunteers (N=8), AUC and t&frac12; increased by 95 and 187%, respectively. Thus, Rozlet should be administered with caution to patients with severe hepatic impairment and after consideration of the risk/benefit in the individual patient.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In a variety of preclinical safety studies conducted in standard animal species, there was no evidence of systemic or target organ toxicity.&nbsp;</p><p>Letrozole showed a low degree of acute toxicity in rodents exposed up to 2000 mg/kg. In dogs letrozole caused signs of moderate toxicity at 100 mg/kg.&nbsp;</p><p>In repeated-dose toxicity studies in rats and dogs up to 12 months, the main findings observed can be attributed to the pharmacological action of the compound. The no-adverse-effect level was 0.3 mg/kg in both species.&nbsp;</p><p>Oral administration of letrozole to female rats resulted in decreases in mating and pregnancy ratios and increases in pre-implantation loss.&nbsp;</p><p>Both in vitro and in vivo investigations of letrozole&#39;s mutagenic potential revealed no indications of any genotoxicity.&nbsp;</p><p>In a 104-week rat carcinogenicity study, no treatment-related tumours were noted in male rats. In female rats, a reduced incidence of benign and malignant mammary tumours at all the doses of letrozole was found.&nbsp;</p><p>In a 104-week mouse carcinogenicity study, no treatment-related tumors were noted in male mice. In female mice, a generally dose-related increase in the incidence of benign ovarian granulosa theca cell tumors was observed at all doses of letrozole tested. These tumors were considered to be related to the pharmacological inhibition of estrogen synthesis and may be due to increased LH resulting from the decrease in circulating estrogen.&nbsp;</p><p>Letrozole was embryotoxic and foetotoxic in pregnant rats and rabbits following oral administration at clinically relevant doses. In rats that had live foetuses, there was an increase in the incidence of foetal malformations including domed head and cervical/centrum vertebral fusion. An increased incidence of foetal malformations was not seen in the rabbit. It is not known whether this was an indirect consequence of the pharmacological properties (inhibition of oestrogen biosynthesis) or a direct drug effect (see sections 4.3 and 4.6).&nbsp;</p><p>Preclinical observations were confined to those associated with the recognised pharmacological action, which is the only safety concern for human use derived from animal studies.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core&nbsp;</u></p><p>&nbsp;</p><p>Silicified&nbsp; microcrystalline&nbsp; cellulose,&nbsp; contains&nbsp; microcrystalline&nbsp; cellulose&nbsp; and&nbsp; silica colloidalanhydrous&nbsp;</p><p>Sodium starch glycollate (Type A)</p><p>Magnesium stearate&nbsp;</p><p>&nbsp;</p><p><u>Tablet coating&nbsp;</u></p><p>&nbsp;</p><p>Polyvinyl Alcohol</p><p>Polyethylene Glycol Titanium</p><p>Dioxide (E171) Talc&nbsp;</p><p>Yellow Iron Oxide (E172)&nbsp;</p><p>Sunset Yellow FCF alumimium lake (E110)&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.&nbsp;</p><p>This medicinal product does not require any special storage conditions.&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister of PVC/PVdC and hard tempered Aluminum foil. Cartons of 10, 14, 28, 30, 100 tablets.&nbsp;</p><p>Not all pack sizes may be marketed&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by: 
EirGen Pharma Ltd. 
Westside Business Park, 
Old Kilmeaden Road, Waterford, 
Ireland. 

For  
SPIMACO 
AlQassim pharmaceutical plant 
Saudi Arabia 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                December 2018. 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>